Is U.S. Physical Therapy, Inc. (USPH) A Good Stock To Buy Now?

Is USPH a bully banal to buy? We came across a bullish thesis connected U.S. Physical Therapy, Inc. connected Quality At A Fair Price’s Substack. In this article, we volition summarize the bulls’ thesis connected USPH. U.S. Physical Therapy, Inc.'s stock was trading astatine $75.72 arsenic of April 20th. USPH’s trailing and guardant P/E were 53.32 and 27.03, respectively, according to Yahoo Finance.

Photographee.eu/Shutterstock.com

U.S. Physical Therapy (USPH) is simply a starring relation of outpatient carnal and occupational therapy clinics crossed the United States, focusing connected pre- and post-operative attraction and benefiting from semipermanent request driven by aging demographics and expanding rehabilitation needs.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The institution has built a consistent track record over decades, combining dependable session enlargement with a disciplined operating exemplary that supports unchangeable currency flows. It has also maintained a shareholder-friendly approach, paying dividends for nearly 15 years, with a existent output of 2.27%, which stands supra its 5-year mean output of 1.82%, implying the banal whitethorn beryllium trading astatine an approximate 17% discount relative to humanities valuation norms.

While USPH has historically delivered beardown dividend growth, this momentum slowed notably successful 2023, with increases falling beneath 5% and bringing the 3-year dividend maturation complaint to conscionable supra 3%. This deceleration raises immoderate interest astir near-term superior instrumentality acceleration, peculiarly for income-focused investors who had grown accustomed to higher maturation rates. However, the broader concern case remains supported by the company’s underlying fundamentals, including resilient demand, a fragmented manufacture operation that allows for continued consolidation, and the imaginable for borderline stableness implicit time.

Despite the caller slowdown successful dividend growth, USPH inactive presents an charismatic full instrumentality profile, with a projected guardant complaint of instrumentality exceeding 15%. If dividend maturation reaccelerates alongside net expansion, the existent valuation discount could narrow, providing some income and superior appreciation upside, making it a compelling accidental for semipermanent investors seeking unchangeable healthcare exposure.

Previously, we covered a bullish thesis on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, which highlighted the company’s displacement toward higher-margin ambulatory care, beardown deleveraging, and important valuation upside driven by improved currency flow. THC’s banal terms has appreciated by astir 52.15% since our coverage. Quality At A Fair Price shares a akin presumption but emphasizes connected dividend yield-driven valuation and dependable outpatient therapy growth.